Latham & Watkins Advises Blackstone Life Sciences on US$750 Million R&D Funding Agreement, the Largest R&D Funding Agreement in 2026
Blackstone has announced that funds managed by Blackstone Life Sciences will provide US$750 million in development funding to Johnson & Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc.
Latham & Watkins LLP represented the client in the transaction with a healthcare finance team led by Bay Area partners Todd Trattner and Haim Zaltzman, with associates William Lane and William Jackson. Advice was also provided on tax matters by Los Angeles partner Eric Cho, with associate Sam Yang; on intellectual property matters by New York partner Rachel Blitzer and Washington, D.C. partner Reba Rabenstein, with associate Drew Roberts; and on healthcare regulatory matters by Washington, D.C. counsel Chad Jennings.